Dr. Reem Olaby is a pharmacist, scientist, and higher-education leader actively engaged in curriculum reform, faculty development, and academic governance.
Her scholarly work focuses on the genetic, epigenetic, and proteomic underpinnings of neurodevelopmental and neurodegenerative disorders, including autism spectrum disorder (ASD), Fragile X syndrome (FXS), and Fragile X–associated tremor/ataxia syndrome (FXTAS).
She is dedicated to translating molecular research into impactful education strategies, clinical training initiatives, and interdisciplinary collaboration.